Shikhar Sharma
Shikhar Sharma
Associate Research Fellow / Group Leader, Pfizer
Adresse e-mail validée de pfizer.com - Page d'accueil
Titre
Citée par
Citée par
Année
Epigenetics in cancer
S Sharma, TK Kelly, PA Jones
Carcinogenesis 31 (1), 27-36, 2010
25352010
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer
EM Wolff, HM Byun, HF Han, S Sharma, PW Nichols, KD Siegmund, ...
PLoS genetics 6 (4), e1000917, 2010
2872010
DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival
DD De Carvalho, S Sharma, JS You, SF Su, PC Taberlay, TK Kelly, ...
Cancer Cell 21 (5), 655-667, 2012
2672012
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA
S Jeong, G Liang, S Sharma, JC Lin, SH Choi, H Han, CB Yoo, G Egger, ...
Molecular and cellular biology 29 (19), 5366-5376, 2009
2192009
The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies
B Vangamudi, TA Paul, PK Shah, M Kost-Alimova, L Nottebaum, X Shi, ...
Cancer research 75 (18), 3865-3878, 2015
1532015
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight
DJ Weisenberger, BN Trinh, M Campan, S Sharma, TI Long, ...
Nucleic acids research 36 (14), 4689-4698, 2008
1362008
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance
S Sharma, DD De Carvalho, S Jeong, PA Jones, G Liang
PLoS genetics 7 (2), e1001286, 2011
1172011
Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development candidate (R …
PP Kung, P Bingham, A Brooun, M Collins, YL Deng, D Dinh, C Fan, ...
Journal of medicinal chemistry 61 (3), 650-665, 2018
342018
Lysine methyltransferase G9a is not required for DNMT3A/3B anchoring to methylated nucleosomes and maintenance of DNA methylation in somatic cells
S Sharma, DS Gerke, HF Han, S Jeong, MR Stallcup, PA Jones, G Liang
Epigenetics & chromatin 5 (1), 1-12, 2012
242012
Emerging therapeutic targets for patients with advanced prostate cancer
F Saad, N Shore, T Zhang, S Sharma, HK Cho, IA Jacobs
Cancer treatment reviews 76, 1-9, 2019
162019
The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review
HS Rugo, I Jacobs, S Sharma, F Scappaticci, TA Paul, ...
Advances in Therapy 37, 3059-3082, 2020
142020
The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations
J Qiu, S Sharma, RA Rollins, TA Paul
Future Medicinal Chemistry 12 (15), 1415-1430, 2020
42020
Discovery of a novel class of potent, selective, and orally bioavailable histone methyltransferase enhancer of zeste homolog 2 (EZH2) inhibitors and the identification of …
PP Kung, S Bergqvist, P Bingham, J Braganza, A Brooun, M Collins, ...
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 253, 2017
12017
First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation
S Sharma, J Chung, S Uryu, A Rickard, N Nady, S Khan, Z Wang, ...
Cancer Research 81 (13 Supplement), 1130-1130, 2021
2021
Intrinsic and Acquired Drug Resistance to LSD1 Inhibitors in SCLC Occurs through a TEAD4 Driven Transcriptional State
W Yan, CY Chung, T Xie, M Ozeck, TC Nichols, J Frey, AR Udyavar, ...
2021
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2 (vol 373, pg 220, 2020)
S Yamazaki, HJ Gukasyan, H Wang, S Uryu, S Sharma
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 375 (1), 238-238, 2020
2020
Ezh2 inhibitor combination therapies
M Kraus, PP Kung, TA Paul, S Sharma, D Verhelle
US Patent App. 16/762,388, 2020
2020
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2
S Yamazaki, HJ Gukasyan, H Wang, S Uryu, S Sharma
Journal of Pharmacology and Experimental Therapeutics 373 (2), 220-229, 2020
2020
Structural rationalization of bioactivity trends that led to identification of the EZH2 development candidate (PF-06821497)
PP Kung, S Bergqvist, P Bingham, J Braganza, A Brooun, M Collins, ...
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 256, 2018
2018
The SMARCA2/4 catalytic activity, but not the bromodomain, is a drug target in SWI/SNF mutant cancers
B Vangamudi, T Paul, PK Shah, MK Alimova, L Nottebaum, X Shi, Y Zhan, ...
Cancer Research 75 (15 Supplement), 3528-3528, 2015
2015
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20